At the last check on Friday, NeuBase Therapeutics Inc.’s (NASDAQ:NBSE) stock was up $0.04, moving up 5.42 percent to $0.71. The average number of shares traded per day over the past five days has been 418,536 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.0520 fall in that time frame. In the last twenty days, the average volume was 339,699, while in the previous 50 days, it was 218,218.
Since last month, NBSE stock retreated -59.64%. Shares of the company fell to $0.6510 on 08/15/23, the lowest level in the past month. A 52-week high of $17.96 was reached on 02/13/23 after having rallying from a 52-week low of $0.65. Since the beginning of this year, NBSE’s stock price has dropped by -81.43% or -$3.0980, and marked a new high 9 times. However, the stock has declined by -96.07% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Financial Health
In the three months ended June 29, NeuBase Therapeutics Inc.’s quick ratio stood at 7.40, while its current ratio was 7.40, showing that the company is able to pay off its debt. Based on annual data, NBSE earned $24000.0 in gross profit and brought in $33.32 million in revenue.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. While analysts expected NeuBase Therapeutics Inc. to report -$2 quarterly earnings, the actual figure was -$2.04 per share, beating the consensus estimate by -2.00%. During the quarter, the company generated -$3.38 million in EBITDA. The liabilities of NeuBase Therapeutics Inc. were 11.09 million at the end of its most recent quarter ended June 29. The value of shareholders’ equity is $2.36 million.
Technical Picture
This quick technical analysis looks at NeuBase Therapeutics Inc.’s (NBSE) price momentum. With a historical volatility rate of 107.42%, the RSI 9-day stood at 20.06% on 17 August.
With respect to its five-day moving average, the current NeuBase Therapeutics Inc. price is down by -6.86% percent or -$0.0520. At present, NBSE shares trade -59.66% below its 20-day simple moving average and -80.39% percent below its 100-day simple moving average. However, the stock is currently trading approximately -81.11% below its SMA50 and -87.70% below its SMA200.
Stochastic coefficient K was 4.10% and Stochastic coefficient D was 3.72%, while ATR was 0.1232. Given the Stochastic reading of 6.63% for the 14-day period, the RSI (14) reading has been calculated as 20.51%. As of today, the MACD Oscillator reading stands at -0.0739, while the 14-day reading stands at -0.1843.
Analyst Ratings
H.C. Wainwright reiterated its a Buy rating on NeuBase Therapeutics Inc. (NASDAQ: NBSE) in a note to investors. The analysts firm has however raised their price target to $18, representing a possible 95.27% increase in the stock price. NeuBase Therapeutics Inc. (NBSE) has been rated Hold by analysts. According to 0 brokerage firms, NBSE is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate NeuBase Therapeutics Inc. stock as buy, with 0 recommending it as overweight.
With a median target price of $200.00, the current consensus forecast for the stock is $200.00 – $200.00. Based on these forecasts, analysts predict NeuBase Therapeutics Inc. (NBSE) will achieve an average price target of $200.00.
